These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. Liebow A; Li X; Racie T; Hettinger J; Bettencourt BR; Najafian N; Haslett P; Fitzgerald K; Holmes RP; Erbe D; Querbes W; Knight J J Am Soc Nephrol; 2017 Feb; 28(2):494-503. PubMed ID: 27432743 [TBL] [Abstract][Full Text] [Related]
7. Chitosan derivatives as nanocarriers for hLDHA inhibitors delivery to hepatic cells: A selective strategy for targeting primary hyperoxaluria diseases. Salido S; Alejo-Armijo A; Parola AJ; Sebastián V; Alejo T; Irusta S; Arruebo M; Altarejos J Int J Pharm; 2022 Nov; 627():122224. PubMed ID: 36181922 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1. Dutta C; Avitahl-Curtis N; Pursell N; Larsson Cohen M; Holmes B; Diwanji R; Zhou W; Apponi L; Koser M; Ying B; Chen D; Shui X; Saxena U; Cyr WA; Shah A; Nazef N; Wang W; Abrams M; Dudek H; Salido E; Brown BD; Lai C Mol Ther; 2016 Apr; 24(4):770-8. PubMed ID: 26758691 [TBL] [Abstract][Full Text] [Related]
9. New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production. Moya-Garzon MD; Rodriguez-Rodriguez B; Martin-Higueras C; Franco-Montalban F; Fernandes MX; Gomez-Vidal JA; Pey AL; Salido E; Diaz-Gavilan M Eur J Med Chem; 2022 Jul; 237():114396. PubMed ID: 35500475 [TBL] [Abstract][Full Text] [Related]
10. Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1. Kukreja A; Lasaro M; Cobaugh C; Forbes C; Tang JP; Gao X; Martin-Higueras C; Pey AL; Salido E; Sobolov S; Subramanian RR Nucleic Acid Ther; 2019 Apr; 29(2):104-113. PubMed ID: 30676254 [TBL] [Abstract][Full Text] [Related]
11. Glycolate and glyoxylate metabolism in HepG2 cells. Baker PR; Cramer SD; Kennedy M; Assimos DG; Holmes RP Am J Physiol Cell Physiol; 2004 Nov; 287(5):C1359-65. PubMed ID: 15240345 [TBL] [Abstract][Full Text] [Related]
12. Infantile Primary Hyperoxaluria Type 1 Treated With Lumasiran in Twin Males. Aldabek K; Grossman OK; Al-Omar O; Fox JA; Moritz ML Cureus; 2022 Jan; 14(1):e21673. PubMed ID: 35237473 [TBL] [Abstract][Full Text] [Related]
13. Lumasiran: First Approval. Scott LJ; Keam SJ Drugs; 2021 Feb; 81(2):277-282. PubMed ID: 33405070 [TBL] [Abstract][Full Text] [Related]
14. Lactate dehydrogenase A inhibitors with a 2,8-dioxabicyclo[3.3.1]nonane scaffold: A contribution to molecular therapies for primary hyperoxalurias. Alejo-Armijo A; Cuadrado C; Altarejos J; Fernandes MX; Salido E; Diaz-Gavilan M; Salido S Bioorg Chem; 2022 Dec; 129():106127. PubMed ID: 36113265 [TBL] [Abstract][Full Text] [Related]
15. Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I. Martin-Higueras C; Luis-Lima S; Salido E Mol Ther; 2016 Apr; 24(4):719-25. PubMed ID: 26689264 [TBL] [Abstract][Full Text] [Related]
16. Targeting kidney inflammation as a new therapy for primary hyperoxaluria? Martin-Higueras C; Ludwig-Portugall I; Hoppe B; Kurts C Nephrol Dial Transplant; 2019 Jun; 34(6):908-914. PubMed ID: 30169827 [TBL] [Abstract][Full Text] [Related]
17. Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay. Fargue S; Knight J; Holmes RP; Rumsby G; Danpure CJ Biochim Biophys Acta; 2016 Jun; 1862(6):1055-62. PubMed ID: 26854734 [TBL] [Abstract][Full Text] [Related]
18. Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria. Frishberg Y; Zeharia A; Lyakhovetsky R; Bargal R; Belostotsky R J Med Genet; 2014 Aug; 51(8):526-9. PubMed ID: 24996905 [TBL] [Abstract][Full Text] [Related]
19. Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening. Mackinnon SR; Bezerra GA; Krojer T; Szommer T; von Delft F; Brennan PE; Yue WW Front Chem; 2022; 10():844598. PubMed ID: 35601556 [TBL] [Abstract][Full Text] [Related]